Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 6:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 393 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Estrogen Receptor-Positive Breast Carcinoma Clear all
Completed Phase 3 Interventional Results available

S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy

NCT01598298
View directory record Official record
Conditions
Breast Cancer, Musculoskeletal Complications, Pain
Interventions
duloxetine hydrochloride, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years · Female only
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
714
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Jonesboro, Arkansas + 475 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2022 · Synced Oct 9, 2026, 6:15 AM EDT
Active, not recruiting Phase 3 Interventional Results available

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

NCT01674140
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, everolimus, exemestane, goserelin acetate, letrozole, leuprolide acetate, tamoxifen citrate, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1,939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1455
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 887 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 9, 2026, 6:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

NCT05386108
View directory record Official record
Conditions
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
Interventions
Elacestrant, Abemaciclib
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
11
States / cities
Fullerton, California • Los Angeles, California • Urbana, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 9, 2026, 6:15 AM EDT
Active, not recruiting Phase 3 Interventional

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

NCT05501886
View directory record Official record
Conditions
Breast Cancer
Interventions
Gedatolisib, Palbociclib, Fulvestrant, Alpelisib
Drug
Lead sponsor
Celcuity Inc
Industry
Eligibility
18 Years and older
Enrollment
701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
71
States / cities
Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 9, 2026, 6:15 AM EDT
Recruiting Phase 1 Interventional

A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

NCT04872166
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Breast Cancer
Interventions
BTX-A51
Drug
Lead sponsor
Edgewood Oncology Inc.
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Lake Mary, Florida • Sarasota, Florida • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 9, 2026, 6:15 AM EDT
Completed Phase 2 Interventional Results available

Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

NCT02291913
View directory record Official record
Conditions
Breast Cancer
Interventions
Everolimus, Exemestane, Tamoxifen, Fulvestrant, Anastrozole, Letrozole, Toremifine
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
8
States / cities
Fort Myers, Florida • Hollywood, Florida • Pensacola, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 9, 2026, 6:15 AM EDT
Completed Phase 2 Interventional Results available

Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

NCT01151046
View directory record Official record
Conditions
Her2 Negative Breast Cancer Patients
Interventions
MM-121, Placebo, Exemestane
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
18
States / cities
Birmingham, Alabama • Glendale, Arizona • Anaheim, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 9, 2026, 6:15 AM EDT
Completed Phase 1 Interventional

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

NCT03725436
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Metastatic Malignant Solid Neoplasm, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Recurrent Breast Carcinoma, TP53 wt Allele, Unresectable Malignant Solid Neoplasm
Interventions
MDM2/MDMX Inhibitor ALRN-6924, Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 9, 2026, 6:15 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

NCT03584009
View directory record Official record
Conditions
Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
Interventions
Venetoclax, Fulvestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
21
States / cities
Phoenix, Arizona • Springdale, Arkansas • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 9, 2026, 6:15 AM EDT
Completed No phase listed Observational

Observational Study to Evaluate Mechanisms of Aromatase Inhibitor Associated Musculoskeletal Symptoms

NCT02118636
View directory record Official record
Conditions
Breast Cancer, Arthralgia
Interventions
Not listed
Lead sponsor
Lynn Henry
Other
Eligibility
21 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Oct 9, 2026, 6:15 AM EDT
Completed Phase 2 Interventional Results available

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

NCT01381874
View directory record Official record
Conditions
Metastatic ER+ Her2- Breast Cancer, Postmenopausal
Interventions
Exemestane, Abiraterone acetate + Prednisone/ Prednisolone + Exemestane, Abiraterone acetate + Prednisone or Prednisolone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
24
States / cities
Muscle Shoals, Alabama • Fresno, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Oct 9, 2026, 6:15 AM EDT
Recruiting Early Phase 1 Interventional

FES BPET-DBT in Newly Diagnosed Breast Cancer

NCT05659797
View directory record Official record
Conditions
Breast Cancer
Interventions
BPET/DBT imaging, 18F-FES
Device · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 9, 2026, 6:15 AM EDT
Completed Phase 2 Interventional Results available

Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer

NCT00546156
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Paclitaxel, Bevacizumab
Drug
Lead sponsor
Ian E. Krop, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
4
States / cities
Boston, Massachusetts • Hooksett, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 9, 2026, 6:15 AM EDT
Active, not recruiting Phase 2 Interventional

CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer

NCT03285412
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Endocrine therapy
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • Danvers, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 9, 2026, 6:15 AM EDT
Completed Phase 2 Interventional Results available

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

NCT01750073
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive, Invasive Breast Carcinoma, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IA Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Radiation Therapy, Therapeutic Conventional Surgery, Trastuzumab
Drug · Other · Radiation + 2 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
4
States / cities
Bellevue, Nebraska • Grand Island, Nebraska • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 9, 2026, 6:15 AM EDT
Completed No phase listed Observational

Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer

NCT00115505
View directory record Official record
Conditions
Breast Carcinoma
Interventions
quality-of-life assessment, Questionnaire Administration
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
227
States / cities
Mobile, Alabama • Fort Smith, Arkansas • Fresno, California + 154 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 9, 2026, 6:15 AM EDT
Terminated No phase listed Observational

Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients

NCT05068726
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
18F Fluoroestradiol Radiopharmaceutical with PET/CT
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
24
States / cities
Flagstaff, Arizona • Cerritos, California • Duarte, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 9, 2026, 6:15 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

NCT02941926
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Letrozole, Goserelin, Leuprolide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
71
States / cities
Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 9, 2026, 6:15 AM EDT
Completed Phase 3 Interventional Results available

Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

NCT00863655
View directory record Official record
Conditions
Breast Cancer
Interventions
Everolimus, Exemestane, Everolimus Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
63
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Anaheim, California + 54 more
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 9, 2026, 6:15 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358
View directory record Official record
Conditions
Breast Neoplasms
Interventions
pembrolizumab, paclitaxel, nab-paclitaxel, liposomal doxorubicin, capecitabine, normal saline, dextrose
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 9, 2026, 6:15 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

NCT04052555
View directory record Official record
Conditions
Bilateral Breast Carcinoma, HER2-Negative Breast Carcinoma, Localized Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions
Berzosertib, Biospecimen Collection, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
14
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 9, 2026, 6:15 AM EDT
Active, not recruiting Phase 1 Interventional

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

NCT07038369
View directory record Official record
Conditions
Advanced Solid Tumors, Breast Cancer, Breast Carcinoma, Breast Neoplasms, ER Positive Breast Cancer, Cervical Cancers, Cervical Neoplasms, Cervical Carcinoma, Triple Negative Breast Cancer, Gynecologic Cancers, Gynecologic Neoplasm, Endometrial Cancer, Endometrial Neoplasm, Endometrial Carcinoma (EC), Fallopian Cancer, Ovarian Carcinoma, Ovarian Cancer, Ovarian Neoplasms, Prostate Cancers, Prostate Carcinoma, Solid Tumors, Neoplasms, Neoplasms by Site, Breast Diseases, Uterine Neoplasms, Genital Neoplasms, Female, Urogenital Neoplasms
Interventions
ATV-1601, ATV-1601 + Fulvestrant
Drug · Combination Product
Lead sponsor
Atavistik Bio, Inc
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Los Angeles, California • Lake Mary, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 9, 2026, 6:15 AM EDT
Recruiting Not applicable Interventional

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

NCT03723928
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Interventions
Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, Quality-of-Life Assessment, Anxiety Questionnaire Administration
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
709
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 456 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 9, 2026, 6:15 AM EDT
Terminated Phase 1 Interventional

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

NCT04185311
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, HER2/Neu Negative, Invasive Ductal Carcinoma, Not Otherwise Specified, Progesterone Receptor Negative, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Ipilimumab, Nivolumab, Talimogene Laherparepvec
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 9, 2026, 6:15 AM EDT